{"analyses":[{"ciLowerLimit":"0.20","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.38","estimateComment":"Cox Proportional Hazard Model (Arm A vs. Arm B) stratified by factors as recorded in IXRS, i.e., presence of del17p (Yes/No), ECOG (0-1/2), # of prior therapies (1-3/4+).","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<0.0001","pValueComment":"Stratified by randomization stratification factors as recorded in IXRS, i.e., presence of del17p (Yes/No), ECOG (0-1/2), # of prior therapies (1-3/4+).","paramType":"Hazard Ratio (HR)","paramValue":"0.28","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Kaplan-Meier Estimates for median PFS and upper 95% CI were not reached for Arm A.","groupId":"OG000","lowerLimit":"45.8","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"14.1","upperLimit":"22.5","value":"16.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"155"},{"groupId":"OG001","value":"155"}],"units":"Participants"}],"description":"PFS per investigator assessment based on the final analysis data cutoff date of 03 September 2021.","dispersionType":"95% Confidence Interval","groups":[{"description":"Acalabrutinib 100 mg orally twice a day","id":"OG000","title":"Arm A: Acalabrutinib Monotherapy"},{"description":"Idelalisib+Rituximab or Bendamustine + Retuximab","id":"OG001","title":"Arm B: Investigator's Choice"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat population including all randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization date to date of disease progression or death due to any cause or data cutoff date on 03Sep2021, whichever came first, regardless of use of subsequent anticancer therapy, until 53 months of follow-up.","title":"Progression-free Survival (PFS) Per Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Months"}